	US 11,858,994 B2
	Biomarkers for cancer immunotherapy
Seiji Matsumoto, Nishinomiya (JP); and Ryuji Suzuki, Ibaraki (JP)
Assigned to Repertoire Genesis Incorporation, Ibaraki (JP); and Hyogo College of Medicine, Nishinomiya (JP)
Appl. No. 16/494,228
Filed by Hyogo College of Medicine, Nishinomiya (JP); and Repertoire Genesis Incorporation, Ibaraki (JP)
PCT Filed Mar. 14, 2018, PCT No. PCT/JP2018/010028 § 371(c)(1), (2) Date Sep. 13, 2019, PCT Pub. No. WO2018/168949, PCT Pub. Date Sep. 20, 2018.
Claims priority of application No. 2017-050105 (JP), filed on Mar. 15, 2017.
Prior Publication US 2020/0024349 A1, Jan. 23, 2020
Int. Cl. C07K 16/02 (2006.01); G01N 33/574 (2006.01); G16B 25/10 (2019.01); C12Q 1/6886 (2018.01); G16H 20/10 (2018.01); G16H 50/30 (2018.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2809 (2013.01) [C07K 16/2815 (2013.01); G01N 33/574 (2013.01); G16B 25/10 (2019.02); G16H 20/10 (2018.01); G16H 50/30 (2018.01); A61K 45/06 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); G01N 2800/52 (2013.01)]

9 Claims

1. A method of treating cancer in a subject who is likely to respond to immunotherapy with an immune checkpoint inhibitor, comprising:

isolating CD8⁺PD-1⁺ cells from a peripheral blood sample of the subject;

determining a sample T cell receptor (TCR) diversity value of the isolated CD8⁺PD-1⁺ T cells to obtain a sample TCR diversity value;

identifying the subject as likely to respond to immunotherapy with an immune checkpoint inhibitor by determining that the sample TCR diversity value is higher than a reference TCR diversity value; and

administering the immune checkpoint inhibitor to the identified subject, and thereby treating the cancer in said subject.